Current treatment of heart failure with reduction of left ventricular ejection fraction

Expert Review of Clinical Pharmacology

Volumn 9, Issue 12, 2016, Pages 1619-1631

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

aldosterone antagonists; angiotensin converting enzyme inhibitors; angotensin receptor blockers; beta blockers; digoxin; Heart failure; hydralazine; nitrates; positive inotropic drugs; sacubitril valsartan

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IVABRADINE; SACUBITRIL PLUS VALSARTAN; CARDIOVASCULAR AGENT;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; DISEASE SEVERITY; HEALTH CARE PERSONNEL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; REVIEW; CLASSIFICATION; DRUG EFFECTS; DRUG THERAPY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME;

CARDIOVASCULAR AGENTS; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84996848876     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2016.1242067     Document Type: Review

References (128)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adultdsummary article. Circulation. 2005;112:1825–1852.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure:a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–e239.•• This paper extensively discusses the treatment of heart failure.
3. Aronow WS., What is the appropriate treatment of hypertension in elders? J Gerontol:Med Sci. 2002;57A:M483–M486.
4. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly:a report of the American college of cardiology foundation task force on clinical expert consensus documents. Developed in collaboration with the American academy of neurology, American geriatrics society, American society for preventive cardiology, American society of hypertension, American society of nephrology, association of black cardiologists, and European society of hypertension. J Am Coll Cardiol. 2011;57:2037–2114.
5. Aronow WS. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontol Med Sci. 2001;56A:M138–M145.
6. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:147–149.
7. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
8. Aronow WS, Ahn C. Elderly diabetics with peripheral arterial disease and no coronary artery disease have a higher incidence of new coronary events than elderly nondiabetics with peripheral arterial disease and prior myocardial infarction treated with statins and with no lipid-lowering drug. J Gerontol:Med Sci. 2003;58A:M573–M575.
9. Sanal S, Aronow WS. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease. J Gerontol:Med Sci. 2003;58A:M1046–M1048.
10. Ghosh S, Aronow WS. Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment. J Gerontol:Med Sci. 2003;58A:M432–M435.
11. Rosendorff C, Lackland DT, Allison M, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease:a scientific statement from the American heart association, American college of cardiology, and American society of hypertension. J Am Coll Cardiol. 2015;65:1998–2038.•• This paper extensively discusses the treatment of heart failure in patients with coronary artery disease.
12. Aronow WS. Management of atrial fibrillation in the elderly. Minerva Med. 2009;100:3–24.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
15. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
16. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
17. Aronow WS. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol. 2001;10:245–252.
18. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195.
19. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacologic therapy for heart failure:an update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol. 2016;68:1476–1488.•• This paper discusses the American College of Cardiology/American Heart Association/Heart Failure Society of America 2016 updated guidelines on new pharmacologic therapy for heart failure.
20. Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–38.
21. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure:results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435.
22. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310.
23. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
24. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828.
25. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450–1456.
26. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677.
27. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691.
28. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670–1676.
29. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 2001;88:1298–1300.
30. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–2318.
31. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057.
32. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351–1357.
33. Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311–317.
34. Vanhoutte PM, Auch-schwelk W, Biondi ML, et al. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol. 1989;28:95S–104S.
35. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800–805.
36. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1994;20:1549–1555.
37. Boger RH, Bodeboger SM, Kramme P, et al. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects:interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol. 1996;42:721–727.
38. Evans MA, Burnett JC, Jr, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol. 1995;25:1445–1450.
39. Katz SD, Radin M, Graves T, et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol. 1999;34:170–176.
40. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction:subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79:115–119.
41. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival:a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425.
42. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol. 1999;33:1920–1925.
43. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581.
44. Lapane KL, Hume AL, Barbour MM, et al. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? J Am Geriatr Soc. 2002;50:1198–1204.
45. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937–942.
46. Jilma B, Krejcy K, Dirnberger E, et al. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci. 1997;60:1859–1866.
47. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
48. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet. 2002;359:1004–1010.
49. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trialdthe losartan heart failure survival study ELITE II. Lancet. 2000;355:1582–1587.
50. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
51. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906.
52. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:the CHARM-alternative trial. Lancet. 2003;362:772–776.
53. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-added trial. Lancet. 2003;362:767–771.
54. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247:1707–1714.
55. Pedersen TR. Six-year follow-up of the Norwegian multicentre study on timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055–1058.
56. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503–510.
57. Kennedy HL, Brooks MM, Barker AH, et al. Beta blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol. 1994;74:674–680.
58. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients R62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction R40%. Am J Cardiol. 1994;74:267–270.
59. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol. 2001;87:780–781.
60. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87:1284–1286.
61. Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation. 1984;69:761–765.
62. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355.
63. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II):a randomised trial. Lancet. 1999;353:9–13.
64. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.
65. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med. 2001;344:651–658.
66. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225.
67. Mann DL, Deswal A, Bozkurt B, et al. New therapeutics for chronic heart failure. Annu Rev Med. 2002;53:59–74.
68. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412–417.
69. Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia:a 3-year randomized study. Stroke. 2002;33:572–577.
70. Moye L, Pfeffer M. Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol. 1997;29:229–236.
71. Exner DV, Dries DL, Waclawiw MA, et al. Beta adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction:a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33:916–923.
72. Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560.
73. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
74. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
75. Zannad F, McMurray JJV, Krun H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
76. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure:results of a veterans administration cooperative study. N Engl J Med. 1986;314:1547–1552.
77. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.
78. Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure:the DIG study. J Am Coll Cardiol. 2001;38:806–813.
79. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403–1411.
80. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–878.
81. Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration and outcomes in women with heart failure:a bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Failure. 2006;8:409–419.
82. Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment? Drugs Aging. 1991;1:98–103.
83. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–926.
84. Abraham WT, Ascheim D, Demarco T, et al. Effects of enrasentan, a nonselective endothelin receptor antagonist in class II to III heart failure:results of the Enrasentan Cooperative Randomized (ENCOR) Evaluation. J Am Coll Cardiol. 2001;38:612.
85. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure. Part II. Circulation. 2002;105:2223–2228.
86. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure:a randomized controlled trial. JAMA. 2004;291:1963–1971.
87. Francis GS, Tang WHW. Vasopressin receptor antagonists. Will the “vaptans” fulfill their promise? JAMA. 2004;291:2017–2018.
88. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.•• LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure.
89. Yandrapalli S, Aronow WS, Mondal P, et al. Limitations of sacubitril/valsartan in the management of heart failure. Am J Therap. 2017;24:xxx–xxx.
90. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954–1961.
91. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–392.
92. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52–60.
93. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–1114.
94. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as suplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation. 1997;96:856–863.
95. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study. Lancet. 2010;376:875–885.•• This study supports the importance of heart rate reduction with ivabradine for improvement of clinical outcomes in heart failure.
96. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
97. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
98. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940.
99. Aronow WS. CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction. Geriatrics. 2005;60(2):24–28.
100. Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
101. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. The MIRACLE ICD trial. JAMA. 2003;289:2685–2694.
102. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
103. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac- resynchronization therapy for the prevention of heart- failure events. N Engl J Med. 2009;361:1329–1338.
104. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.
105. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–1843.
106. Brignole M, Botto G, Mont L, et al. Cardiac resynchronizaton in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation:a randomized trial. Eur Heart J. 2011;32:2420–2429.
107. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;103:1280–1284.
108. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475.
109. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure:preliminary results of the PROFILE study [abstract]. Circulation. 1993;88(supplI):I–301.
110. Uretsky BF, Jessup F, Konstan MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation. 1990;82:774–780.
111. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998;339:1810–1816.
112. Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure:main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223–231.
113. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1–6.
114. Hampton JR, Van Veldhusisen DJ, Kleber FX, et al. Randomized study of effect of ibopamine on survival in patients with advanced heart failure. Lancet. 1997;349:971–977.
115. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure:insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 2000;138:78–86.
116. Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. 2015;16:29060–29068.
117. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA. 2002;287:1531–1540.
118. Teerlink JR, Massie BM. Nesiritide and worsening of renal function. The emperor’s new clothes? Circulation. 2005;111:1459–1461.
119. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491.
120. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905.
121. O’Connor CM, Starling RC, Hernandez PW, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
122. Athanasuleas CL, Stanley AW, Jr, Buckberg GD, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol. 2001;37:1210–1213.
123. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705–1717.
124. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–1616.
125. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival i ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–1625.
126. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. dysfunction. N Engl J Med. 2016;374:1511–1520.•• In patients with ischemic cardiomyopathy, the incidences of all-cause mortality, cardiovascular death, and death from any cause or hospitalization for cardiovascular causes were significantly lower over 10 years in patients who underwent coronary artery bypass grafting plus medical therapy than in those randomized to medical therapy alone.
127. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for endstage heart failure. N Engl J Med. 2001;345:1435–1443.
128. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251.